IRD (Opus Genetics) Momentum Rank: 3 (As of Aug. 23, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRD Opus Genetics Inc IRD
20 GF Score
Price $4.05
GF Value $0.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Opus Genetics Momentum Rank?

Opus Genetics IRD -1.70% 20 Momentum Rank is 3 as of Aug. 23, 2026, which is 50% above its 10-year median of 2.00. GuruFocus rates IRD with a GF Score™ of 20/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Opus Genetics has the Momentum Rank of 3.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Opus Genetics Momentum Rank Related Terms

IRD vs TTRX, VRXA, IFRX: Momentum Rank Comparison

For the Biotechnology subindustry, Opus Genetics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Momentum Rank falls into.


IRD
20GF Score
Opus Genetics Inc IRD
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 3 mean?
Opus Genetics (IRD) has a Momentum Rank of 3 as of Aug. 23, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Opus Genetics and its competitors. This is 50% above median its historical median of 2.00. Over the past decade, Opus Genetics' Momentum Rank has ranged from 1.00 to 9.00.
Is Opus Genetics' Momentum Rank too high?
Opus Genetics' current Momentum Rank of 3 is 50% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Opus Genetics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Momentum Rank compare to TTRX and VRXA?
Opus Genetics' Momentum Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Opus Genetics' own Momentum Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Opus Genetics and its competitors. Opus Genetics's current Momentum Rank is 3, which is 50% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $4.05 — trading 1344.6% above its estimated fair value. The current Momentum Rank is 3, which is 50% above median its 10-year median of 2.00. Opus Genetics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Opus Genetics (IRD), the current Momentum Rank is 3 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $4.05 is trading 1344.6% above its estimated GF Value™ of $0.28. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Momentum Rank: 3 (50% above median its 10-year median of 2.00)
  • GF Value™: $0.28 vs. price of $4.05 (1344.6% above fair value)
  • GF Score™: 20/100 with 6 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score

Get the complete analysis for IRD

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.05
Price
$0.28
GF Value